PTK2B and central nervous system cancer: Of note, the additive effects observed in Pyk2- and FAK-silenced cells in the presence of the inhibitors gefitinib, tocilizumab, burixafor, and DMPQ suggest that multiple MCM factors are involved in the Pyk2 and FAK activation that modulates the cell cycle in glioma cells (Figure 6b–f).